B. Riley Securities Initiates Coverage On Neuronetics with Buy Rating, Announces Price Target of $5
B. Riley Securities analyst Madison El-Saadi initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and announces Price Target of $5.
Stocks · News reference
Neuronetics Appoints Nir Naor CFO, Effective July 23,
Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Reiterates Buy on Neuronetics, Maintains $6 Price Target
BTIG analyst Sam Eiber reiterates Neuronetics (NASDAQ:STIM) with a Buy and maintains $6 price target.
8-K filing — Neuronetics, Inc. (STIM)
Filed: 2026-08-17 AccNo: 0001193125-26-354051 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
BTIG Maintains Buy on Neuronetics, Raises Price Target to $6
BTIG analyst Sam Eiber maintains Neuronetics (NASDAQ:STIM) with a Buy and raises the price target from $5 to $6.